TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04074876

Intervention type: DEVICE
Intervention: Pulmonary echography
Description: Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~* 0: normal pattern (A-lines)~* 1: multiple B lines (at least 3 for field), well defined.~* 2: B lines coalescent~* 3: consolidation of any dimension
Study: NCT04322539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Oral VEGFR inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT02702596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement-Based Integrated Care
Description: Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement-Based Integrated Care
Description: Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Education Fotonovela
Description: Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Education
Description: The the use of a pamphlet to educate people about depression.
Study: NCT01401959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m\^2 IV Days 1 and 8, every 21 days for six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 6 mg/kg IV Day 1 every 21 days
Study: NCT00600054

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nimotuzumab (anti EGFR humanized monoclonal antibody)
Description: 150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
Study: NCT00879879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: 50 mg losartan taken daily by mouth in capsule form for 1 year
Study: NCT03239691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478 for oral use
Description: Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo available as matching capsules for oral administration
Study: NCT02514954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biochaperone® Combo
Description: Subcutaneous injection of an individualized dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix25
Description: Subcutaneous injection of an individualized dose
Study: NCT03445182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthesia with conventional syringe
Description: Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthesia with conventional syringe + Dentalvibe
Description: Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL
Study: NCT01346215

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium
Description: 5000 UI/mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium
Description: 5000 UI/mL
Study: NCT03064581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
Study: NCT04304209

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total mesorectal excision
Description: total mesorectal excision after neoadjuvant treatment
Study: NCT01791556

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV-1 viral load testing
Study: NCT05278637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg/day x 4 weeks, Aspirin 325mg/day x 4 weeks. or Aspirin 325mg/day x 4 weeks, Aspirin 81mg/day x 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg BID x 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg BID x 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90mg BID x 4 weeks
Study: NCT00645788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg matching placebo powder formulation twice a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (Cipro Inhale, BAYQ3939)
Description: 48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
Study: NCT03407339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared Oral Care intervention
Description: One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level.
Study: NCT00862108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: mg/kg dose: 0.7\~1.2mg/kg PO daily morning intake 8 weeks
Study: NCT00159562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individual education
Description: individual sessions of psycho-education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group education
Description: group psycho-education in 10 weekly sessions and then a session every third month for two years
Study: NCT02165176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabis
Study: NCT03539224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Description: DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Description: Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
Study: NCT01721980

Intervention type: DRUG
Group type: OTHER
Intervention: GLPG0974

Intervention type: DRUG
Group type: OTHER
Intervention: GLPG0974

Intervention type: DRUG
Group type: OTHER
Intervention: GLPG0974
Study: NCT04294784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)
Description: Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;SHR-1210 200mg, ivdrip,d1,Q21d.
Study: NCT00063999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01775410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolverine System to perform atherectomy
Study: NCT03208400

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: virtual reality exposure
Description: one-session exposure conveyed via virtual reality technology
Study: NCT03169179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit and Bupa Boost app
Description: Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
Study: NCT04294784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin-bound Paclitaxel
Description: Albumin-bound Paclitaxel 100 mg/m2,ivdrip,d1,d8,d15,Q28d,or Albumin-bound Paclitaxel 125-130 mg/m2,ivdrip,d1,d8,Q21d,or Albumin-bound Paclitaxel 260mg/m2,ivdrip,d1,Q21d;
Study: NCT04430582

Intervention type: OTHER
Intervention: Cognitive Assessment (not diagnostic)
Description: Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.
Study: NCT00976300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
Study: NCT03673228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Relapse Prevention Intervention
Description: This intervention consists of 4 components:~1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Counseling
Description: Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
Study: NCT04430582

Intervention type: OTHER
Intervention: Cognitive Assessment (not diagnostic)
Description: Cognitive testing will assess premorbid intelligence, working memory and attention, verbal memory and delayed memory, executive function, and psychomotor speed.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG will take place during screening visit.

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: ECG will take place during screening visit.
Study: NCT01721980

Intervention type: DRUG
Group type: OTHER
Intervention: GLPG0974

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04304209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch and wait
Description: Watch and wait for cCR patients after neoadjuvant treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch and wait
Description: Watch and wait for cCR patients after neoadjuvant treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watch and wait
Description: Watch and wait for cCR patients after neoadjuvant treatment
Study: NCT03480880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral Index
Description: Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
Study: NCT03262103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 0.5 mg
Description: 0.5 mg IT once/week (week 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 0.5 mg
Description: 0.5 mg IT once/week (week 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 1.0 mg
Description: 1.0 mg IT once/week (week 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) Poly ICLC 1.0 mg
Description: 1.0 mg IT once/week (week 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Poly ICLC
Description: 1 mg IM twice weekly (weeks 3-6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Poly ICLC
Description: 1 mg IM twice weekly (weeks 3-6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Poly ICLC
Description: 1 mg IM twice weekly (weeks 3-6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) Poly ICLC
Description: 1 mg IM twice weekly (weeks 3-6)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: as per standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: as per standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: as per standard care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: as per standard care
Study: NCT02680444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Mindful-Reappraisal Exercise
Description: Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Reappraisal-Only Exercise
Description: A reappraisal of daily negative events by examining the positive aspects.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered Event Recall Exercise
Description: Recall a negative event that took place that day.
Study: NCT01214590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VascuActive device
Description: self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
Study: NCT02464254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus positive affect
Description: Subjects will be randomized to a physical activity goal and will receive the positive affect component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity plus education
Description: Subjects will be randomized to a physical activity goal and will receive the educational component.
Study: NCT05779358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Expectancy and gluten
Description: Effect of expectancy to receive gluten and/or actual gluten intake
Study: NCT03131895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release.
Study: NCT05028855

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral autoregulation assessment
Description: Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.
Study: NCT00824070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin hydrochloride
Description: Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride
Description: Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
Study: NCT04571294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of para-aortic lymphnodes (PALN)
Description: During pancreaticoduodenectomy, para-aortic lymphnodes (PALN) will be removed for the surgeon
Study: NCT02927210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethandrolone Undecanoate
Description: Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injections that look like the DMAU injections but with no active ingredients
Study: NCT02318420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The PartoMa intervention
Description: WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The PartoMa intervention
Description: WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training